Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries

Autor: Morten S. Thomsen, Leslie Citrome, Chen-Chung Liu, Ludovic Samalin, Ricardo P. Garay, Christoph U. Correll, Ahcène Hameg, Pierre-Michel Llorca
Přispěvatelé: Centre d'accueil et d'échanges scientifiques internationaux [Villemoisson-sur-Orge, France] (CRAVEN), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Graduate Institute of Network Learning Technology, National Central University [Taiwan] (NCU), Psychiatric Department, Sanofi-Aventis
Jazyk: angličtina
Rok vydání: 2016
Předmět:
medicine.medical_specialty
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
Cariprazine
Schizoaffective disorder
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
media_common.cataloged_instance
Humans
Pharmacology (medical)
Valbenazine
European Union
Registries
European union
Psychiatry
ComputingMilieux_MISCELLANEOUS
Brexpiprazole
media_common
Pharmacology
Encenicline
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior
business.industry
[SCCO.NEUR]Cognitive science/Neuroscience
[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
General Medicine
medicine.disease
United States
030227 psychiatry
3. Good health
Clinical trial
chemistry
Clinical Trials
Phase III as Topic
Psychotic Disorders
Schizophrenia
Schizophrenic Psychology
business
Cognition Disorders
030217 neurology & neurosurgery
Antipsychotic Agents
Zdroj: Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy, Taylor & Francis, 2016, 17 (7), pp.921-936. ⟨10.1517/14656566.2016.1149164⟩
ISSN: 1465-6566
1744-7666
DOI: 10.1517/14656566.2016.1149164⟩
Popis: In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future.Recent (post 2013) phase III clinical trials of schizophrenia-targeted therapies were found in US and EU clinical trial registries. Two hundred fifty-three trials were identified, that included 16 investigational compounds. The antipsychotics brexpiprazole and cariprazine have been approved in the US, and although both are dopamine D2 receptor partial agonists, they differ markedly in their pharmacodynamic profiles. Encenicline and valbenazine are first-in-class candidates for treatment of cognitive impairment associated with schizophrenia (CIAS) and tardive dyskinesia, respectively. Eleven add-on compounds were previously approved for other therapeutic indications and are for the most part being studied at academic medical centers and smaller pharmaceutical companies for negative symptoms and CIAS or for specific populations (comorbidities, antipsychotic-induced obesity).Promising new agents are emerging for schizophrenia and schizoaffective disorder. In addition to better-tolerated antipsychotics that treat positive symptoms, we could see the arrival of the first effective drug for negative symptoms and CIAS, which would strongly facilitate the ultimate goal of recovery in persons with schizophrenia.
Databáze: OpenAIRE
Externí odkaz: